Oseltamivir phos 75 MG capsule UD 10S
Ended Awarded Last action
- Contract number
- SPE2DR26FQPV4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $69,250
Award facts
- Contract value 100% obligated
- $69,250.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $69.25K firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Oseltamivir Phosphate 75 mg capsules in unit dose packaging. The award, issued on December 4, 2025, with an ultimate completion date of December 5, 2025, carries no set-aside designation, indicating the contractor competed in an unrestricted procurement environment. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.99B umbrella contract awarded November 13, 2025, that establishes the framework for supplying pharmaceuticals to Department of Defense military healthcare facilities worldwide.
The PPV-G GEN V represents DLA's broader $30.3B acquisition strategy to streamline pharmaceutical procurement across the federal military medical system through regional prime vendor contracts. DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through numerous delivery orders issued between October and December 2025, supplying a comprehensive portfolio spanning branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals to support DoD healthcare operations. The company's established performance on diverse therapeutic categories positions it as a critical supplier within the federal pharmaceutical supply chain, with this delivery order for Oseltamivir—an antiviral medication commonly used for influenza treatment—exemplifying the routine pharmaceutical requirements fulfilled under the PPV-G GEN V contract structure.
Quick answers
Who was awarded contract SPE2DR26FQPV4?
SPE2DR26FQPV4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 4, 2025.
How much is contract SPE2DR26FQPV4 worth?
The government has obligated $69,250 on SPE2DR26FQPV4.
Is contract SPE2DR26FQPV4 an order under another contract?
Yes. SPE2DR26FQPV4 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQPV4 competed?
The extent of competition for SPE2DR26FQPV4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award